Big Pharma Pushes FDA To Decouple Inspections From Drug Approval Applications

By /

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s approach to pre-approval inspections.

Scroll to Top